Patents Examined by Zohreh A. Fay
  • Patent number: 10406232
    Abstract: A composition for treating atopic dermatitis in animals containing active compositions of ceramides for skin barrier protection, omega 3 and omega 6 fatty acids for reducing pruritus and botanical extracts for inhibiting 5-lipoxygenase activity, histamine release while modulating the immune system. The active compositions are placed in a soft dough oral delivery system.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: September 10, 2019
    Assignee: VETS PLUS, INC.
    Inventors: Daniel J. DuBourdieu, Rajiv Lall, Ajay Srivastava
  • Patent number: 10406127
    Abstract: Amorphous solid dispersions suitable for oral delivery comprising fenretinide or an analog thereof and at least one matrix polymer, and processes for making the dispersions, are disclosed. Also disclosed are solid oral formulations comprising the amorphous solid dispersions, as well as uses thereof for the prevention and/or treatment of diseases or conditions treatable by fenretinide, including but not limited to cancers, conditions associated with a lipid imbalance, cystic fibrosis, osteoporosis, conditions associated with inflammation or opportunistic infections, and other diseases such as diabetes, obesity, dry-form age-related macular degeneration.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: September 10, 2019
    Inventors: Aimesther Betancourt, Marc Lemieux, Roch Thibert
  • Patent number: 10398647
    Abstract: A hydrogel composition is provided. The hydrogel composition includes polyglutamic acid (PGA) containing maleimide groups, and polyethylene glycol (PEG) containing terminal thiol groups, wherein the hydrogel composition has a pH value ranging from 4.0 to 6.5. A drug delivery system is also provided. The drug delivery system includes the above-mentioned hydrogel composition, and a pharmaceutically active ingredient encapsulated in the hydrogel composition.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: September 3, 2019
    Inventors: Wen-Hsuan Chiang, Yu-Wen Lo, Felice Cheng, Maggie Lu, Ya-Ling Chiu
  • Patent number: 10391059
    Abstract: Oral preparations of microcapsules and nanoparticles including an inhibitor of the mammalian target of rapamycin. The preparations are intended to assist with the treatment and prevention of cancer, neurocognitive dysfunction, genetically predisposed disorders, and age-related disorders. The embodiments discussed address the present need for alternative preparations or manufacturing processes that ensure efficacy while improving other performance characteristics such as storage stability, biodistribution, dosage cost, etc.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: August 27, 2019
    Assignee: Rapamycin Holdings, Inc.
    Inventors: Neal K Vail, Dana M Vaughn
  • Patent number: 10391185
    Abstract: The invention provides a multimodal ultrasound and photoacoustic contrast agent based on polymeric microparticles having a gas core and carrying at least one photoacoustic agent in its shell that stabilizes the gas core, for use in ultrasound and photoacoustic imaging. Such multimodal ultrasound and photoacoustic contrast agent is also suitable as a carrier of drugs and for use in photodynamic therapy, and for tissue imaging ex vivo.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: August 27, 2019
    Assignees: Fujifilm VisualSonics, Inc., RWTH Aachen
    Inventors: Fabian Kiessling, Twan Lammers, Stanley Fokong Nyongamsen, Katrin Suppelt
  • Patent number: 10383813
    Abstract: A cosmetic composition for whitening skin and a preparation method thereof. The composition comprises the following components: pearl powder, pearl extract, glycyrrhiza glabra aqueous solution, hydrolyzed conchiolin protein and pea extract. The contents of the pearl powder and the pearl extract are not both zero, and the glycyrrhiza glabra aqueous solution contains 0.5 to 5.0% of the glycyrrhiza glabra extract.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: August 20, 2019
    Assignee: OSM Biology Co., Ltd.
    Inventors: Gang Huo, Xueyang Deng, Ping Ma
  • Patent number: 10385040
    Abstract: Indoline sulfonamide compounds that can inhibit DapE and/or bacterial metallo-?-lactamases (MBLs), such as NDM-1, are disclosed. Also disclosed are methods of treating an individual suffering from a bacterial infection using the indoline sulfonamide compounds disclosed herein.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: August 20, 2019
    Inventors: Daniel Paul Becker, Richard C. Holz, Tahirah K. Heath, Cory Reidl, Anna Starus
  • Patent number: 10376475
    Abstract: The present invention relates to a novel method of treatment of acne in a human patient in need thereof, comprising administering topically to said patient an effective amount of the compound 3,5-Dihydroxy-4-isopropyl-trans-stilbene (Compound 1) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: August 13, 2019
    Inventors: Javier Cote-Sierra, Susan H. Smith, Steven M. Frey
  • Patent number: 10376489
    Abstract: A method of treating a chronic wound in a subject in need of such treatment is provided. The method includes administering to the subject at least one antioxidant agent in an amount effective to treat the wound. In some versions, the antioxidant agent is ?-tocopherol or N-acetyl cysteine, or a combination of these compounds. In other versions, a method of preparing a chronic wound animal model is provided.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: August 13, 2019
    Assignee: The Regents of the University of California
    Inventors: Manuela Martins-Green, Sandeep Dhall, Danh Do, Neal Schiller
  • Patent number: 10357453
    Abstract: A method comprising: administering an effective amount of a topical dipyridamole to a subject in need thereof due to a disorder selected from the group consisting of keratitis, corneal abrasion and corneal ulcer.
    Type: Grant
    Filed: December 30, 2018
    Date of Patent: July 23, 2019
    Assignee: O.D. Ocular Discovery Ltd.
    Inventor: Moshe Rogosnitzky
  • Patent number: 10350294
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: July 16, 2019
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Patent number: 10350161
    Abstract: The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: July 16, 2019
    Assignee: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Ioanna Koutri, Anastasia Kalaskani, Andreas Kakouris, George Gotzamanis
  • Patent number: 10351525
    Abstract: A compound which is a thienolate of formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein R1, R3, Ring A1, n and Ring A2 are as defined herein, are found to be useful in inhibiting metallo-beta-lactamase and therefore in potentiating the activity of beta lactamase antibiotics. The compound can be used alone or in combination with a rhodanine of formula (II) or a pharmaceutically acceptable salt thereof: (II) wherein R3, Ring A1, n, Ring A2, L and Ring B are as defined herein. Treatment or prevention of bacterial infection in combination with beta-lactam antibiotic agents is also provided.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: July 16, 2019
    Assignee: Oxford University Innovation Limited
    Inventors: J├╝rgen Brem, Sander S. Van Berkel, Michael A. McDonough, Christopher J. Schofield
  • Patent number: 10336779
    Abstract: Gold(I) complexes and gold(I) dithiocarbamate polymers as anticancer therapeutics. The Au(I) ion within the gold(I) complexes is coordinated to two phosphine ligands. The repeating unit formed by Au(I) ion coordinating to dithiocarbamate ligands are connected by Au(I)-Au(I) interactions within the gold(I) dithiocarbamate polymers. Also disclosed are methods of synthesis, pharmaceutical compositions incorporating the gold(I) complexes, pharmaceutical compositions incorporating the gold(I) dithiocarbamate polymers, and methods of treating cancer.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: July 2, 2019
    Assignee: King Fahd University of Petroleum and Minerals
    Inventors: Anvarhusein A. Isab, Muhammad Altaf, Adam Ahmed Abdallah Seliman
  • Patent number: 10322112
    Abstract: Methods for modulating quorum sensing in certain Gram-negative bacteria having multiple QS systems including Las, Rhl, and Pqs with associated receptors (LasR, RhlR and PqsR) which are modulated by small molecule modulators, particularly non-native modulators. Certain combinations of modulators of Las, Rhl and Pqs exhibit improved inhibition of virulence in comparison to the respective individual modulators. In particular, certain combinations of modulators exhibit improved inhibition in nutritionally depleted environments. More specifically, certain combinations of modulators exhibit improved inhibition in environments depleted in phosphate and/or environments depleted in iron. Nutrient depleted environments can mimic environments associated with bacterial infection in humans and non-human animals. The methods are useful in particular for modulating QS in Pseudomonas and Burkholderia.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: June 18, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Helen Blackwell, Michael Welsh
  • Patent number: 10314927
    Abstract: The present invention relates to a method of preparation of formulations of gadolinium metal complexes of the macrocyclic chelator DOTA, which further comprise a small excess of free DOTA. The method uses controlled conditions such that excess gadolinium is present as a precipitate of gadolinium oxide, with filtration to remove the excess, prior to the addition of a defined excess of DOTA chelator. Also provided is a method of preparation of MRI contrast agents based on Gd-DOTA.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: June 11, 2019
    Assignee: GE HEALTHCARE AS
    Inventors: Mikkel Jacob Thaning, Andreas Richard Meijer
  • Patent number: 10307384
    Abstract: Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: June 4, 2019
    Assignee: ZeaVision LLC
    Inventor: Dennis L. Gierhart
  • Patent number: 10308649
    Abstract: A composition and method for treating autoimmune disease includes administering an effective amount of an aryl hydrocarbon receptor (AhR) ligand. The AhR ligand includes 11-Cl-BBQ, 10-Cl-BBQ, an analog of 11-Cl-BBQ, or combination thereof. The AhR ligand is administered topically, orally, transdermally, intravenously, subcutaneously, or with a nanoparticle. The AhR ligand induces regulatory T cells (AhR-Tregs). AhR-Treg cells block the differentiation of cytotoxic T-lymphocytes (CTL). The AhR ligand activates AhR in CD4+ T cells to induce CD4+ AhR-Tregs that suppress the development of effector CTL, thereby suppressing the development of CTL that attack host cells in graft versus host disease (GVHD) or ?-cells in the pancreas in diabetes mellitus type 1 (T1DM). The AhR ligand can also suppress development of CTL independently of Foxp3+ regulatory T cell induction. The AhR ligand can therefore be used to treat autoimmune diseases characterized by an absence of functional Foxp3+ regulatory T cell.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: June 4, 2019
    Assignee: Oregon State University
    Inventors: Nancy I. Kerkvliet, Siva Kumar Kolluri
  • Patent number: 10307409
    Abstract: A combination of a muscarinic cholinergic receptor agonist, a non-anticholinergic antiemetic agent and a non-selective, peripheral anticholinergic agent for the treatment of hypocholinergic disorders of the central nervous system.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: June 4, 2019
    Assignee: Chase Pharmaceuticals Corporation
    Inventors: Thomas N. Chase, Kathleen E. Clarence-Smith
  • Patent number: 10294204
    Abstract: Provided is a fluorescent compound represented by the following [Chemical Formula 1] and a method for preparing the same: wherein each of X, Y, R1, R2, R3 and n is the same as defined in the specification.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: May 21, 2019
    Assignee: BIOACTS CO., LTD.
    Inventors: Jin Woo Park, Su-Jung Jang, Kiwon Kim, Gyeong Rim Shin, Bongkyu Lee